1061742-69-5

Basic information

• Product Name: tert-butyl (2R)-4-[(benzyloxy)carbonylamino]-2-[1,1'-(biphenyl-4-yl-sulfonyl)-(benzyloxy)amino]butanoate
• Synonyms: tert-butyl (2R)-4-[(benzyloxy)carbonylamino]-2-[1,1'-(biphenyl-4-yl-sulfonyl)-(benzyloxy)amino]butanoate
• CAS NO: 1061742-69-5
• Molecular Weight: 630.762
• Mol File: 1061742-69-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl (2R)-4-[(benzyloxy)carbonylamino]-2-[1,1'-(biphenyl-4-yl-sulfonyl)-(benzyloxy)amino]butanoate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (2R)-4-[(benzyloxy)carbonylamino]-2-[1,1'-(biphenyl-4-yl-sulfonyl)-(benzyloxy)amino]butanoate(1061742-69-5)
• EPA Substance Registry System: tert-butyl (2R)-4-[(benzyloxy)carbonylamino]-2-[1,1'-(biphenyl-4-yl-sulfonyl)-(benzyloxy)amino]butanoate(1061742-69-5)

Safety Data

• Hazardous Substances Data: 1061742-69-5(Hazardous Substances Data)

Upstream product

• 1061742-67-3 N-(benzyloxy)biphenyl-4-sulfonamide 
• 849773-54-2 tert-butyl (2S)-4-{[(benzyloxy)carbonyl]amino}-2-hydroxybutanoate 
• 40371-50-4 S-4-benzyloxycarbonylamino-2-hydroxybutyric acid 
• 2687-43-6 O-benzylhydoxylamine hydrochloride 
• 1623-93-4 4-diphenylsulfonyl chloride 

Downstream Products

• 1061742-72-0 C₃₁H₃₀N₂O₇S 
• 1061742-43-5 (R)-benzyl 3-(N-(benzyloxy)biphenyl-4-ylsulfonamido)-4-(hydroxyamino)-4-oxobutylcarbamate 
• 1061742-73-1 C₃₇H₄₅N₃O₇SSi 

Relevant articles and documents

Diagnostic agents selective against metalloproteases

The invention relates to aryl-sulphonamido compounds endowed with affinity against metallo proteases MMP, having formula (I) below wherein R, R1, R2, R3, G and n have the meanings reported in the specification, properly la

Potent arylsulfonamide inhibitors of tumor necrosis factor-α converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models

Activated leukocyte cell adhesion molecule (ALCAM) plays a relevant role in tumor biology and progression. Our previous studies showed that ALCAM is expressed at the surface of epithelial ovarian cancer (EOC) cells and is released in a soluble form by ADAM-17-mediated shedding. This process is relevant to EOC cell motility and invasiveness, which is reduced by nonspecific inhibitors of ADAM-17. For this reason, ADAM-17 may represent a new useful target in anticancer therapy. Herein, we report the synthesis and biological evaluation of new ADAM-17 inhibitors containing an arylsulfonamidic scaffold. Among the new potential inhibitors, two very promising compounds 17 and 18 were discovered, with a nanomolar activity for ADAM-17 isolated enzyme. These compounds proved to be also the most potent in inhibiting soluble ALCAM release in cancer cells, showing a nanomolar activity on A2774 and SKOV3 cell lines